General Information of Drug (ID: DM047HI)

Drug Name
Vamorolone Drug Info
Synonyms
vamorolone; 13209-41-1; UNII-8XP29XMB43; VBP-15; 8XP29XMB43; CHEMBL2348780; 17,21-Dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione; A-Methyl-9,11-dehydro Prednisolone; (8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-one; Vamorolone [USAN]; VBP-15 free alcohol; VBP 15; EINECS 236-177-8; AC1MHYKY; Vamorolone (USAN/INN); SCHEMBL143459; GTPL9247; A)-17,21-dihydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione; ZINC33650317
Indication
Disease Entry ICD 11 Status REF
Duchenne muscular dystrophy 8C70.1 Approved [1]
Duchenne dystrophy 8C70 Phase 2 [2]
Inflammatory bowel disease DD72 Phase 1 [3]
Multiple sclerosis 8A40 Phase 1 [3]
Rheumatoid arthritis FA20 Phase 1 [3]
Cross-matching ID
PubChem CID
3035000
CAS Number
CAS 13209-41-1
TTD Drug ID
DM047HI

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CORT125281 DMHBOUX Prostate cancer 2C82.0 Phase 2 [4]
ISIS-GCCR DMICMNU Diabetic complication 5A2Y Phase 2 [5]
ORIC-101 DMR12S0 Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
AZD9567 DMAXHC0 Rheumatoid arthritis FA20 Phase 1 [3]
A-348441 DM25CBW Type-2 diabetes 5A11 Phase 1 [6]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G Discovery agent N.A. Investigative [7]
(11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE DMTPQ84 Discovery agent N.A. Investigative [8]
deoxycorticosterone DMW6YLS Discovery agent N.A. Investigative [8]
LGD-5552 DM67KWM Discovery agent N.A. Investigative [9]
AL-43 DMLEDHR Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucocorticoid receptor messenger RNA (GCR mRNA) TTOZRK6 GCR_HUMAN Agonist [3]

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 215239
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
6 Synthesis and activity of novel bile-acid conjugated glucocorticoid receptor antagonists. Bioorg Med Chem Lett. 2006 Dec 1;16(23):6086-90.
7 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
8 Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. Gln-642 plays an important role in steroid recognition and binding. J Biol Chem. 2000Jun 23;275(25):19041-9.
9 Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19244-9.
10 Differentiation of in vitro transcriptional repression and activation profiles of selective glucocorticoid modulators. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1721-7.